Beam Therapeutics's top three insider shareholders as of April 17, 2026 are Llc Fmr (Other, 4.01Mn shares), Venture Partners Ix, Llc Arch (TenPercentOwner, 2.95Mn shares), Venture Partners Ix, Llc Arch (TenPercentOwner, 2.95Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Llc Fmr | - | 0 | 4,007,424 | 15 Feb, 2024 |
| Venture Partners Ix, Llc Arch | - | 28,111 | 2,921,519 | 02 Jul, 2021 |
| Venture Partners Ix, Llc Arch | - | 28,111 | 2,921,519 | 02 Jul, 2021 |
| Kristina Burow | - | 12,067 | 2,921,519 | 02 Jul, 2021 |
| John M. Evans | Ceo | 1,047,205 | 0 | 06 Apr, 2026 |
| Llc Fmr | - | 0 | 841,231 | 08 Oct, 2025 |
| Giuseppe Ciaramella | President | 230,216 | 0 | 02 Apr, 2026 |
| Giuseppe Ciaramella | President | 218,406 | 0 | 06 Apr, 2026 |
| Christine Bellon | Chief Legal Officer | 115,667 | 0 | 02 Apr, 2026 |
| Christine Bellon | Chief Legal Officer | 109,711 | 0 | 06 Apr, 2026 |
| Amy Simon | Chief Medical Officer | 109,114 | 0 | 02 Apr, 2026 |
| Sravan Kumar Emany | Chief Financial Officer | 105,456 | 0 | 02 Apr, 2026 |
| Sravan Kumar Emany | Chief Financial Officer | 105,456 | 0 | 02 Apr, 2026 |
| John M. Evans | Ceo | 0 | 103,000 | 02 Nov, 2022 |
| Amy Simon | Chief Medical Officer | 102,735 | 0 | 06 Apr, 2026 |
| Terry-Ann Burrell | Chief Financial Officer | 82,637 | 0 | 29 Apr, 2024 |
| Bethany J Cavanagh | Svp, Finance And Treasurer | 51,171 | 0 | 06 Apr, 2026 |
| Llc Fmr | - | 0 | 14 | 29 Oct, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Giuseppe Ciaramella | Common Stock | D | 11,810 | $24.58 | 218,406 | D | S |
| 01 Apr, 2026 | John M. Evans | Common Stock | D | 30,078 | $24.58 | 1,047,205 | D | S |
| 01 Apr, 2026 | Christine Bellon | Common Stock | D | 5,956 | $24.58 | 109,711 | D | S |
| 01 Apr, 2026 | Amy Simon | Common Stock | D | 6,700 | $24.58 | 102,735 | D | S |
| 01 Apr, 2026 | Bethany J Cavanagh | Common Stock | D | 3,242 | $24.58 | 51,171 | D | S |
| 31 Mar, 2026 | Giuseppe Ciaramella | Common Stock | A | 40,000 | $0.00 | 230,216 | D | A |
| 31 Mar, 2026 | Amy Simon | Common Stock | A | 31,750 | $0.00 | 109,114 | D | A |
| 31 Mar, 2026 | Christine Bellon | Common Stock | A | 20,000 | $0.00 | 115,667 | D | A |
| 31 Mar, 2026 | Bethany J Cavanagh | Common Stock | A | 20,000 | $0.00 | 54,813 | D | A |
| 31 Mar, 2026 | Sravan Kumar Emany | Common Stock | A | 31,750 | $0.00 | 105,456 | D | A |
| 24 Feb, 2026 | Giuseppe Ciaramella | Common Stock | A | 35,000 | $17.00 | 225,216 | D | M |
| 24 Feb, 2026 | Giuseppe Ciaramella | Common Stock | D | 35,000 | $32.00 | 190,216 | D | S |
| 24 Feb, 2026 | Giuseppe Ciaramella | Stock Option (Right to Buy) | D | 35,000 | $0.00 | 397,313 | D | M |
| 31 Jan, 2026 | Bethany J Cavanagh | Stock Option (Right to Buy) | A | 40,000 | $0.00 | 40,000 | D | A |
| 31 Jan, 2026 | Giuseppe Ciaramella | Stock Option (Right to Buy) | A | 80,000 | $0.00 | 80,000 | D | A |
| 31 Jan, 2026 | Christine Bellon | Stock Option (Right to Buy) | A | 40,000 | $0.00 | 40,000 | D | A |
| 31 Jan, 2026 | Amy Simon | Stock Option (Right to Buy) | A | 88,500 | $0.00 | 88,500 | D | A |
| 31 Jan, 2026 | Sravan Kumar Emany | Stock Option (Right to Buy) | A | 63,500 | $0.00 | 63,500 | D | A |
| 22 Jan, 2026 | Bethany J Cavanagh | Common Stock | D | 6,198 | $35.00 | 34,813 | D | S |
| 22 Jan, 2026 | Christine Bellon | Common Stock | D | 1,371 | $34.00 | 95,667 | D | S |